Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF Source: Eur Respir J 2013; 42: 252-271 Year: 2013
Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Source: Eur Respir J 2016; 48: 516-525 Year: 2016
Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? Source: Eur Respir J 2012; 40: 161-168 Year: 2012
Molecular diagnosis of tuberculosis in a north Italian clinical setting: results of routine use of a commercial LCR-based test Source: Eur Respir J 2001; 18: Suppl. 33, 360s Year: 2001
Clinical utility of the Xpert MTB/RIF test in induced sputum Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015
How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? Source: Eur Respir J 2015; 45: 549-554 Year: 2015
Diagnostic yield of AFB smear, culture, LiPA, GeneXpert: A clinician’s perspective Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015
Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis Source: Eur Respir J 2012; 40: 442-447 Year: 2012
The new horizons of molecular diagnosis: do we still need conventional microbiology? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012
The yield of bronchoscopy in sputum Xpert MTB/Rif negative tuberculosis in the Xpert era. Source: Virtual Congress 2020 – Diagnostic challenges in tuberculosis Year: 2020
New-entrant screening for tuberculosis at port of entry in the U.K.: Is it time to change policy? Source: Annual Congress 2012 - Tuberculosis: epidemiological and public health features Year: 2012
Clinical utility of a lateral flow serologic test in the rapid diagnosis of pulmonary TB in a public-private mix for DOTS setting in Iloilo City, Philippines Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011
Use of Xpert MTB/RIF Ultra assays among paediatric tuberculosis experts in Europe Source: Eur Respir J, 51 (5) 1800346; 10.1183/13993003.00346-2018 Year: 2018
Introduction: CPET in clinical practice. Recent advances, current challenges and future directions Source: Eur Respir Monogr 2018; 80: x-xxv Year: 2018
Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding Source: Eur Respir J, 58 (6) 2100257; 10.1183/13993003.00257-2021 Year: 2021
A comparison between the efficiency of the Xpert MTB/RIF assay and nested PCR in identifying mycobacterium tuberculosis during routine clinical practice Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 2 Year: 2014
Clinical trial landscape for M/XDR-TB: current evidence and future perspectives Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019
Laboratory investigations of infection in COPD: current best practice and future possibilities Source: Annual Congress 2008 - PG1 - EU GRACE network full-day course: Antibiotics or not: from acute bronchitis to acute exacerbation of chronic bronchitis Year: 2008
Tuberculosis diagnosis in rural Namibia using gene Xpert MTB/RIF testing Source: International Congress 2016 – Microbiology: bronchoalveolar lavage (BAL) and PCR Year: 2016